Cocke shoots holes in his entire thesis prematurely when he states his buddy died at an early age, then goes on to compare EXAS new DNA colon cancer test to old technology developed by previous management. The whole idea behind the DNA test is EARLY DETECTION in stage 1,2,3, and then treat the cancer while you still can. Test earlier, more often, and then operate before you land in hospice care. It does not have to have a near perfect detection rate to save tens of thousands of lives each year you dope. The tests he compares Cologard to are nearly useless for early detection.
The fact is, that no upstart financial analyst has any business trying to evaluate medical diagnostic tests. They simply don't understand, nor do they want to when it doesn't fit their stock position. He spends two thirds of his argument looking at "numbers" from previous failed products developed by the companies previous owners and management. A BASELESS ARGUMENT. If a contest like this doesn't teach an individual investor to do his own DD, nothing ever will. My prediction is this Cocke will be at his fourth investment house when JPM runs him over in his trade in the next six months.
False information by design. Don't think intent is to collapse price- - that won't work, just wiggle it down some. Then try something else in a few weeks. Would like to see management address some of this misinformation but I think they want to stay above it.